Oral anticoagulation in patients with gastrointestinal bleeding and new-onset atrial fibrillation : A population-based registry-linkage study
Loading...
Access rights
openAccess
CC BY
CC BY
publishedVersion
URL
Journal Title
Journal ISSN
Volume Title
A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä
This publication is imported from Aalto University research portal.
View publication in the Research portal (opens in new window)
View/Open full text file from the Research portal (opens in new window)
View publication in the Research portal (opens in new window)
View/Open full text file from the Research portal (opens in new window)
Unless otherwise stated, all rights belong to the author. You may download, display and print this publication for Your own personal use. Commercial use is prohibited.
Date
Major/Subject
Mcode
Degree programme
Language
en
Pages
14
Series
Journal of Internal Medicine, Volume 298, issue 5, pp. 450-463
Abstract
Background: Limited data exist on the prevalence of gastrointestinal bleeding (GIB) in patients with new-onset atrial fibrillation (AF) and the impact of GIB on the initiation of oral anticoagulation (OAC) therapy. Methods: A population-based registry-linkage study included all patients diagnosed with new-onset AF in Finland during 2010–2018 who had available laboratory data and a definite indication for OAC therapy. The primary outcome was OAC initiation within 90 days following AF diagnosis. Factors associated with OAC initiation were assessed using modified Poisson regression. Results: Among 117 997 patients with new-onset AF, 6628 (5.6%) had GIB, of which 5336 occurred more than 30 days prior to AF diagnosis, and 1292 were temporally (±30 days) associated with new-onset AF (GIBTAF). Patients with GIB compared to those without GIB were older (mean age 78.3 vs. 75.3 years), more frequently men (48.5% vs. 41.9%), and had more comorbidities. The occurrence of GIB was associated with a lower probability of initiating OAC (RR 0.84, 95% CI 0.81–0.86). Among patients with GIB, an obscure origin of GIB (RR 0.93, 95% CI 0.88–0.99) or GIBTAF reduced the likelihood of OAC initiation (RR 0.72, 95% CI 0.66–0.79). The initiation of OAC did not depend on the known GIB bleeding site (lower vs. upper). Overall, the initiation of OAC therapy increased from 2010 to 2018 but remained consistently lower in patients with GIB. Conclusion: Prior and concurrent GIB is common among patients with new-onset AF, and despite the overall increasing use of OACs, they remain less utilized in patients with GIB.Description
Publisher Copyright: © 2025 The Author(s).
Other note
Citation
Jolkkonen, S, Putaala, J, Teppo, K, Mustonen, P, Jaakkola, J, Aro, A, Halminen, O, Lehtonen, O, Haukka, J, Linna, M, Hartikainen, J, Airaksinen, K E J & Lehto, M 2025, 'Oral anticoagulation in patients with gastrointestinal bleeding and new-onset atrial fibrillation : A population-based registry-linkage study', Journal of Internal Medicine, vol. 298, no. 5, pp. 450-463. https://doi.org/10.1111/joim.70018